Korea OKs Gilead’s Sovaldi, All Eyes On Pricing
This article was originally published in PharmAsia News
Executive Summary
South Korea has granted approval to Gilead’s Sovaldi as a therapy for adults with genotype 1, 2, 3 or 4 chronic hepatitis C in combination with other therapies. All eyes are now on whether all four genotypes will be covered by the national health insurance scheme and at what price the drug will be sold in the country, as the company negotiates for reimbursement with the government over the next few months.